PYRUKYND is also approved for adults with PK deficiency in the U.S. and Europe, and a marketing application for PYRUKYND in thalassemia is currently under review by the European Commission. In the U.S ...

Many people discover they have fatty liver disease during a routine health check-up. They walk into a clinic for a regular ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues ...

AstraZeneca received FDA approval for Calquence with venetoclax, creating the first all oral, fixed duration regimen for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. The ...

Also known as metastatic breast cancer (mBC), Stage IV means the disease has spread to other parts of the body, and approximately 1 in 3 people with breast cancer develop mBC.³ In Lynn’s case, her ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced milestones in the expected timeline for the ...

Addis is a city at a crossroads. A massive redevelopment project is reshaping Ethiopia’s capital into what Prime Minister ...

DAYTONA BEACH, Fla. (AP) — Tyler Reddick had trouble corralling his young son on a Disney cruise and then inside a cramped motorhome in the days leading into the Daytona 500. Rookie Reddick turns 9 ...

AstraZeneca has secured U.S. FDA approval for Calquence (acalabrutinib) in combination with venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...